Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study

Anna Bozzini1 · Luca Nicosia1 · Giancarlo Pruneri2,3 · Patrick Maisonneuve4 · Lorenza Meneghetti1 · Giuseppe Renne2 · Andrea Vingiani2,3 · Enrico Cassano1 · Mauro Giuseppe Mastropasqua6,7

Abstract

Purpose To compare the efficacy of contrast-enhanced spectral mammography, with ultrasound, full field digital mammography and magnetic resonance imaging in detection and size estimation of histologically proven breast tumors.

Methods This open-label, single center, prospective study, included 160 dense breast women with at least one suspicious mammary lesion evaluated by ultrasound, full field digital mammography and magnetic resonance imaging in whom a mammary tumor was histologically proven after surgery performed at the European Institute of Oncology between January 2013 and December 2015. Following the complete diagnostic procedure, the patients were further investigated by contrast-enhanced spectral mammography prior to surgery.

Results Overall, the detection rate of malignant breast lesions (in situ and invasive) was 93.8% (165/176) for contrast-enhanced spectral mammography, 94.4% (168/178) for ultrasound, 85.5 (147/172) for full field digital mammography and 97.7% (173/177) for magnetic resonance imaging. Radiological measurements were concordant with the post-surgical pathological measurements of the invasive tumor (i.e., within 5 mm) in: 64.6% for contrast-enhanced spectral mammography, 62.0% for ultrasound, 45.2% for full field digital mammography ($p < 0.0001$) and 69.9% for magnetic resonance imaging ($p = 0.28$); underestimated in: 17.4% for contrast-enhanced spectral mammography, 19.6% for ultrasound, 24.2% for full field digital mammography ($p = 0.03$) and 6.7% for magnetic resonance imaging ($p = 0.0005$); and overestimated in: 16.2% for contrast-enhanced spectral mammography, 16.6% for ultrasound, 16.6% for full field digital mammography and 22.7% for magnetic resonance imaging ($p = 0.02$).

Conclusions Our data suggest that contrast-enhanced spectral mammography improves on full field digital mammography and is comparable to ultrasound and magnetic resonance imaging in terms of detection sensitivity and size estimation of malignant lesions in dense breasts.

Keywords Contrast-enhanced spectral mammography · Ultrasound · Full field digital mammography · Magnetic resonance · Breast malignant lesions

Abbreviations

| Abbreviation | Description                     |
|--------------|---------------------------------|
| CESM         | Contrast enhanced spectral mammography |
| BC           | Breast cancer                   |
| US           | Ultrasound                      |
| MRI          | Magnetic resonance imaging      |
| FFDM         | Full field digital mammography  |
| BI-RADS      | Breast imaging reporting and data system |
| VABB         | Vacuum-assisted breast biopsy   |

Introduction

Contrast-enhanced spectral mammography (CESM) is a recently developed imaging technique relying on visualization of iodinated contrast agent uptake, proposed as a new complementary approach to breast imaging [1, 2]. At present, breast cancer (BC) diagnosis and staging rely mainly on three diagnostic techniques: full field digital mammography (FFDM), ultrasound (US), mammography and magnetic...
resonance imaging (MRI). FFDM is best suited to studying breast tissue with a predominantly adipose component [1, 2] as its lower sensitivity in dense, fibro-glandular breasts may lead to increased false negative rates and cancer size underestimation, especially in young patients [3, 4]. US, on the other hand, is particularly suitable for studying dense breasts, but its overall diagnostic efficacy is affected by the high false positive rate [3]. MRI is characterized by high sensitivity, independent of breast density, but its specificity is limited by high (up to 19%) false positive rates [5]. Moreover, evidence suggests that MRI is associated with treatment delay without an associated improvement in margin clearance at surgery and clinical outcome [6].

In this scenario, CESM, which is similar to MRI in taking advantage of the differential enhancement between neoplastic and normal tissue, has recently gained momentum as an innovative and clinically useful method for preoperative breast assessment [7–10].

In CESM, a pair of images are acquired for each view: one low-energy image (LE), similar to a standard mammogram, and one high-energy image (HE), which is optimized for the detection of iodine contrast agent uptake; the two images are then combined to produce an image where glandular tissue texture is suppressed and contrast uptake is highlighted. Exposure techniques for acquisition of LE CESM images are similar to those used for conventional digital mammography.

In particular, CESM has better sensitivity without a loss of specificity compared with mammography alone and improves lesion delineation through visualization of contrast medium uptake within breast lesions. There is an increased cancer detection rate for CESM over MG, comparable to MRI, and also an improvement in size estimation [11–13].

In patients with dense breasts, it has been recently shown that CESM is more sensitive than traditional imaging techniques, irrespective of patient menopausal status, and shows significantly lower false positive rates than MRI and in some preliminary study of the last years CESM, can replace the standard mammogram in symptomatic women [7–15].

The main aim of our study was to compare CESM with conventional imaging techniques in pre-surgical breast assessment of women with dense breasts, using tumor size estimation as a pre-specified endpoint.

**Methods**

**Patients**

Ethics Committee approval was obtained for this retrospective study as well as patients’ informed consent.

The study population consisted of 160 women diagnosed and treated at the European Institute of Oncology in Milan, between January 2013 and December 2015. These patients were characterized as having dense breasts (ACR 3 and 4 on FFDM), and presented at least one suspicious mammary lesion evaluated by US, FFDM and MRI, subsequently confirmed as a malignant lesion (in situ or invasive) at histo-pathological evaluation of the surgical specimen. Prior to surgery, all the patients received a diagnosis of C4 or C5 by fine-needle aspiration, or a B4 or B5 diagnosis by core biopsy or vacuum-assisted (VABB) breast biopsy [16]. For a full listing of the inclusion and exclusion criteria, see Table 1.

All of the patients were examined pre-operatively using a CE-Marked, Senographe Essential, full field digital system, with SenoBright option (GE Healthcare, Chalfont St. Giles, UK), for dual-energy CESM acquisitions. In brief, this involved a catheter being placed into the antecubital vein of

| Table 1 | Inclusion criteria: Full list of the inclusion and exclusion criteria of the study |
| --- | --- |
| Eligibility criteria | 1. Previous digital mammography and ultrasound and magnetic resonance imaging 2. Suspicious or malignant diagnosis by FNAC (C4 or C5), by core biopsy (CB) or VABB (B4 or B5) 3. Dense breast (ACR class 3 or 4 on mammography) 4. Capable and willing to comply with study procedures, having signed the informed consent form 5. Breast size compatible with the dimensions of the image detector 6. In sufficiently good health to undergo standard breast cancer care and CESM examination |
| Exclusion criteria | 1. High risk of adverse events related to iodinated contrast agents 2. Previously included in this study 3. Participating in, or having participated in another clinical trial(s) within the 30 days precedent 4. Previous breast reconstructive surgery or breast implant(s) 5. Concomitant or previous radiotherapy to the thorax area or systemic chemotherapy 6. Proven or supposed pregnancy |
the arm contra-lateral to the suspicious breast lesion, and a one-shot intravenous injection of 1.5 ml/Kg of contrast agent (Visipaque® 320, GE) using a power injector. Two minutes after the contrast agent administration, bilateral cranio-caudal (CC) and mediolateral oblique (MLO) views were obtained with standard compression at 2 different energy exposures (high and low). For the high energy acquisitions, Molybdenum/Cupper or Rhodium/Cupper filters were used instead of traditional Molybdenum/Molybdenum, Rhodium/Rhodium or Molybdenum/Rhodium, which were used for low energy acquisitions. The low- and high-energy images were automatically combined by the scanner software to produce subtracted images reflecting contrast agent content. The total X-ray dose delivered to the patient was 20%-30% higher than that delivered for a standard digital mammogram, according to the thickness of the breast during the compression (4–10 N) [7]. The total examination time was roughly six minutes.

One breast radiologist, with 20 years of experience, blinded to the original reports of US, FFDM and MRI, evaluated the images of CESM.

Patients were surgically operated within 6 weeks of diagnosis. In keeping with the study goals of comparing CESM breast lesion detection rates with US, FFDM, and MRI, and of ascertaining their relative ability to estimate breast tumor size, the surgical pathology report was adopted as the reference standard. To this end, the surgical specimens were sampled and evaluated immediately after surgical excision, prior to formalin fixation, to avoid shrinkage due to the fixation process, and ultimately allowing a more reliable comparison with in vivo data. In cases of palpable, grossly visible DCIS lesions, the extent was reported as the greatest dimension at gross evaluation; in case of non-palpable lesions, the serial sequential sampling method was used, by mapping tissue blocks, as previously reported [17].

As regards lesion size, the results were coded as follows: negative (tumor not detected by test method); concordant (tumor detected and size was within 5 mm of pathology dimension); underestimated (tumor detected but size underestimated by < 5 mm); overestimated (tumor detected but size overestimated by > 5 mm).

We also performed a secondary analysis of possible interactions between detection rates and size estimation for each technique and traditional pathological characteristics (multifocality, histotypes, coexistence of an in situ component, histological grade, peritumoral vascular invasion, and pT), as possible confounding factors.

**Statistical methods**

The Clopper-Pearson exact method was used to estimate 95% confidence intervals for proportions. The McNemar test was used to assess the agreement of CESM findings with those of US, FFDM and MRI. The Fisher exact test was used to assess difference of results across subgroups of patients. Analyses were performed with SAS version 9.2 (Cary NC). All p-values are two-sided (Figs. 1, 2, 3, and 4).

**Results**

Clinico-pathological characteristics of the 160 patients included in the study are detailed in Table 2. Post-surgery pathological examination revealed 178 breast lesions (163 invasive tumors and 15 non-invasive tumors). CESM, FFDM, and MRI were not performed in one and two and
Overall, the detection rate of breast malignant lesions (invasive and in situ) was 93.8\% for CESM, 94.4\% for US, 85.5\% for FFDM and 97.7\% for MRI. In particular, the detection rate in invasive tumors was 98.1\% for CESM, 98.2\% for US \((p = 1.00)\), 86.0\% for FFDM \((p < 0.0001)\) and 99.4\% for MRI \((p = 0.50)\) (Table 3). Somewhat lower were the detection rates for non-invasive tumors: 46.7\% for CESM, 53.3\% for US \((p = 1.00)\), and 80.0\% for both FFDM and MRI \((p = 0.06)\) (Table 4).

Size estimation was evaluated only for the histologically proven invasive tumors (Table 3). The histological diagnoses were invasive ductal carcinoma NST (131), invasive lobular carcinoma (21), acinic carcinoma (2), mixed ductal–lobular carcinoma (8) and malignant phyllodes tumor (1). The six cases of invasive tumor, respectively, due to peripheral location of the lesions or technical reasons.

The rate of unnecessary intervention for breast lesions considered suspicious at radiological examination has increased over the last decade [18]. Furthermore, although the radiological methods currently used for early BC detection have contributed to a significant reduction of mortality, they are characterized by some degree of inconsistency. In particular, standard mammography is the only screening modality shown to reduce BC mortality rates, but its sensitivity and specificity can be affected by breast tissue density. The diagnostic efficacy of US, the imaging technique most commonly used in combination with FFDM, is closely related to operator experience. Finally, while MRI is the most sensitive breast imaging method, being capable of detecting tumor angiogenesis through contrast enhancement [19–23], it is affected by high rates of false positive results [20–23]. In this regard, CESM, based on the differential enhancement of neoplastic and normal tissue and coupling sensitivity to specificity, could represent a novel reliable tool for early detection of breast tumors [7–15].
Table 2 Patients characteristics

(a) Ages of patients included in the study

| Age (year) | N (%) |
|------------|-------|
| <40        | 5 (3.1%) |
| 40–49      | 71 (47.3%) |
| 50–59      | 59 (36.9%) |
| 60–69      | 16 (10%) |
| 70+        | 9 (5.6%) |
| <50        | 76 (47.5%) |
| 50+        | 84 (52.5%) |

(b) Patients characteristics (N=160): Histology, receptor status, and staging

| pT (ypT) | N (%) |
|----------|-------|
| 0        | 4 (2.5) |
| 1mi      | 2 (1.2) |
| 1a       | 24 (15.0) |
| 1b       | 66 (41.2) |
| 1c       | 2 (1.2) |
| 2        | 46 (28.7) |
| 3        | 14 (8.8) |
| 4        | 1 (0.6) |
| Missing  | 1 (0.6) |

| pN       | N (%) |
|----------|-------|
| 0        | 83 (51.9) |
| 1        | 42 (26.2) |
| 2        | 12 (7.5) |
| 3        | 16 (10.0) |
| X        | 6 (3.7) |
| Missing  | 1 (0.6) |

| Grade    | N (%) |
|----------|-------|
| G1       | 27 (16.9) |
| G2       | 70 (43.7) |
| G3       | 57 (35.6) |
| Missing  | 6 (3.7) |

| ER       | N (%) |
|----------|-------|
| ER+      | 95 |
| ER−      | 65 |
| Missing  | 0 |

| PgR      | N (%) |
|----------|-------|
| PgR+     | 95 |
| PgR−     | 65 |
| Missing  | 0 |

| Ki 67    | N (%) |
|----------|-------|
| Ki 67 low (<20%) | 88 |
| Ki 67 high (>20%) | 70 |
| Missing  | 2 |

| Her2/neu | N (%) |
|----------|-------|
| Her2/neu+ | 90 |
| Her2/neu− | 67 |
| Missing  | 3 |

\(^a\)Final characteristics of the worst nodule when more than one present per patient

\(^b\)Or not evaluable
that the resulting images and radiation dose are very similar to those obtained with FFDM. The high-energy image is adapted to impart a minimal dose; as a consequence, the total CESM examination dose is about 20% higher than a standard FFDM examination, but still within the EUREF Guidelines levels for digital mammography screening [16].

In keeping with previous data reporting a 0.2–0.4% risk, we did not observe any severe adverse reaction [24].

In this study, we evaluated the efficacy of CESM in a well characterized series of dense breast patients with histologically proven malignant mammary lesions, comparing its diagnostic performance with US, FFDM and MRI. We

Table 3: Detection rate and size estimation in invasive tumors

| Lesions | US | FFDM | CESM | MRI |
|---------|----|------|------|-----|
|         | N  | Rate (95% CI) | N  | Rate (95% CI) | N  | Rate (95% CI) | N  | Rate (95% CI) |
| ALL     | 163 | 98.2% (94.7–99.6%) | 157 | 86.0% (79.6–91.0%) | 161 | 98.1% (94.7–99.6%) | 162 | 99.4% (96.6–100%) |
| Performance CESM | 1.00 | <0.0001 | – | 0.50 |

(a) Detection rate versus pathology

| Lesions detected | US | FFDM | CESM | MRI |
|------------------|----|------|------|-----|
| Lesions detected | 160 | 135 | 158 | 162 |
|                  | 98.2% (94.7–99.6%) | 86.0% (79.6–91.0%) | 98.1% (94.7–99.6%) | 99.4% (96.6–100%) |
| Performance CESM | 1.00 | <0.0001 | – | 0.50 |

(b) Lesion size versus pathology

| Negative | US | FFDM | CESM | MRI |
|----------|----|------|------|-----|
|         | 3  | 22   | 3    | 1   |
| Performance CESM* | 1.00 | <0.0001 | – | 0.50 |
| Underestimated | 32 | 38   | 28   | 11  |
|                  | 19.6% (13.8–26.6%) | 24.2% (17.7–31.7%) | 17.4% (11.9–24.1%) | 6.7 (3.4–11.8%) |
| Performance CESM* | 0.56 | 0.04 | – | 0.0005 |
| Concordant | 101 | 71   | 104  | 114 |
|                  | 62.0% (54.0–69.4) | 45.2% (37.3–53.4) | 64.6% (56.7–72.0) | 69.9% (62.3–78.9) |
| Performance CESM* | 0.56 | <0.0001 | – | 0.28 |
| Overestimated | 27 | 26   | 26   | 37  |
|                  | 16.6% (11.2–23.2%) | 16.6% (11.1–23.3%) | 16.2% (10.8–22.8%) | 22.7% (16.5–29.9%) |
| Performance CESM* | 1.00 | 1.00 | – | 0.02 |

FFDM was not evaluable for 6 patients, CESM for 2 patients and MRI for 1 patient.

FFDM full field digital mammography, CESM contrast enhanced spectral mammography, US ultrasound, MRI magnetic resonance imaging.

The performance of CESM with respect to US, MRI and FFDM is evaluated with McNemar Test p-value.

Table 4: Detection rate in intraductal tumors

| Lesions | Detection rate |
|---------|----------------|
|         | US N | Rate (95% CI) | FFDM N | Rate (95% CI) | CESM N | Rate (95% CI) | MRI N | Rate (95% CI) |
| ALL     | 15   | 8    | 53% (27–79%) | 12   | 80% (52–96%) | 7     | 47% (21–73%) | 12   | 80% (52–96%) |
| DIN1c/ (DCISG1) | 4   | 2    | 50% (7–93%) | 3    | 75% (19–79%) | 1     | 25% (1–81%)  | 3    | 75% (19–79%) |
| DIN2/ (DCISG2) | 7   | 5    | 71% (29–96%) | 6    | 86% (42–100%) | 3     | 43% (10–82%) | 6    | 86% (42–100%) |
| DIN3/ (DCISG3) | 4   | 1    | 25% (1–81%)  | 3    | 75% (19–79%) | 3     | 75% (19–79%) | 3    | 75% (19–79%) |

Performance wrt CESM* | 1.00 | 0.06 | – | 0.06 |

* wrt with respect to

FFDM full field digital mammography, CESM contrast enhanced spectral mammography, US ultrasound, MRI magnetic resonance imaging, LIN lobular intraepithelial neoplasia, DIN ductal intraepithelial neoplasia.

The performance of CESM with respect to US, MRI and FFDM is evaluated with McNemar Test p-value.
found that CESM properly detected 165 of the 176 lesions analyzed overall, yielding to a 93.7% detection rate, in turn similar to US and MRI and significantly higher than FFDM. CESM sensitivity was particularly high in invasive tumor patients, where it correctly detected all except three cases, corresponding to a 98% detection rate in this subgroup. A high sensitivity of CESM has previously been reported by other groups [7–10]. In particular, Dromain et al. [7] found CESM to have better sensitivity (93% vs 90%) and specificity (63% versus 47%) compared with FFDM plus US. The authors also showed that CESM correctly estimated tumor size, using the final histologic report as a reference.

Likewise, Jochelson et al. [10], who examined 52 women with newly diagnosed breast carcinomas, reported that CESM equaled MRI sensitivity, with a significantly lower false positive rate (2 vs 13 cases in CESM and MRI, respectively). These data were reproduced by Fallenberg et al. [8, 9], who also reported that CESM was more accurate than MRI in lesion size estimation; Fallenberg et al. also reported the correct estimation of lesion tumor size in two recent studies on 118 patients and 178 patients [9, 11].

CESM sensitivity was less than 50% for the 15 in situ lesions seen in our cohort. These were more efficiently detected by FFDM and MRI (approximately 80% detection rate each). This is in contrast to Lalji et al. [25], who have recently reported that the low-energy CESM images are non-inferior to FFDM images. Our results are not entirely surprising, taking into account that non-invasive lesions are usually associated with tissue microcalcifications, which are efficiently detected by FFDM.

Kuhl hypothesized the high sensitivity of MRI in identifying non-invasive lesions could be attributed to contrast media extravasation and accumulation around intraductal proliferations [26]. This process does not occur using the iodinated media in CESM analysis, as reported in previous studies focusing on CT scan methods [27–29].

Tumor size estimation plays a pivotal role in guiding surgical management in breast cancer patients [30–36]. Our data provides evidence that CESM combines high detection rates for invasive lesions with accurate size estimation. CESM assessment of invasive tumor size was concordant with pathological data in 64.6% of lesions, a figure similar to that obtained by US and MRI, but significantly higher than FFDM (p < 0.0001). The cases in which CESM underestimated cancer size (17% of the cases) consisted mainly of lobular BC, large tumors (pT3/4) and multifocal BC. MRI has previously been reported to be more efficient than CESM in detecting multifocal, multicentric, and synchronous tumors [10], but with a significantly increased false positive rate, consequently the CESM could not suffer from typical MRI clinical limitations.

Iodinated contrast media in highly vascularized tissues, provides an enhancement effect stronger than in normal surrounding breast tissue [20–23]. It is therefore tempting to speculate that CESM sensitivity largely relies on tumor vascularization [37]: interestingly, neo-angiogenesis has been reported to occur heterogeneously in lobular carcinomas in studies assessing micro-vessel density by immunohistochemistry for endothelial markers [38]. Collectively, these data suggest that CESM could actually be less sensitive in properly addressing tumor size in large, multifocal lobular carcinomas.

In our study, performed on large cohort of patients, we confirm that CESM provides additional information with consistent improvement of the cancer diagnosis in dense breasts and assessment in tumor size.

The major limitation of our study is that all patients in our cohort had dense breasts and presented with radiologically suspicious mammary lesions that were subsequently histologically diagnosed as malignant. These inclusion criteria may have led to a selection bias and consequently, that our results should be translated with caution to an unselected, radiologically “naive” population. Moreover, this design meant that we were not able to retrieve data about CESM specificity.

Also, we were not able to assess the ability of CESM to evaluate in situ lesion dimensions, since available pathological data were discontinuous. Furthermore, the number of in situ lesions was too small to draw statistically significant conclusions about any putative difference in detection rate among different intraductal carcinoma subtypes.

Our data prompt us to hypothesize that CESM could enter into clinical practice for its sensitivity in early detection of breast tumors, as a valid adjunct in the surgical management of BC patients [39]. Further studies are needed to define the future role of CESM in breast cancer staging and management.

**Funding** Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.

**Compliance with ethical standards**

**Conflict of interest** We have no conflicts of interest to declare.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773–1783. https://doi.org/10.1056/NEJMoa052911

2. Berg WA, Gutierrez L, Ness Aiver MS et al (2004) Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 233:830–849. https://doi.org/10.1148/radiol.2333031484

3. Bosch AM, Kessels AG, Beets GL et al (2003) Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol 48:285–292. https://doi.org/10.1016/j.ejrad.2009.06.012

4. Fasching PA, Heusinger K, Loehberg CR et al (2006) Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. Eur J Radiol 60:398–404. https://doi.org/10.1016/j.ejrad.2006.08.002

5. Saslow D, Boetes C, Burke W et al (2007) American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89. https://doi.org/10.3322/canjclin.57.2.75.Erratum(2007)CA Cancer J Clin57:185

6. Blescher RJ, Ciocca RM, Egleston BL et al (2009) Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 209:180–187. https://doi.org/10.1016/j.jamcollsurg.2009.04.010

7. Dromain C, Thibault F, Muller S et al (2011) Dual-energy contrast-enhanced digital mammography: initial clinical results. Eur Radiol 21:565–574. https://doi.org/10.1007/s00330-010-1944-y

8. Fallonberg EM, Dromain C, Diekmann F et al (2014) Contrast-enhanced spectral mammography versus MRI: initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol 24:256–264. https://doi.org/10.1007/s00330-013-3007-7

9. Fallonberg EM, Dromain C, Diekmann F et al (2014) Contrast-enhanced spectral mammography: does mammography provide additional clinical benefits or can some radiation exposure be avoided? Breast Cancer Res Treat 146:371–381. https://doi.org/10.1007/s10549-014-3023-6

10. Joehlson MS, Dershaw DD, Sung JS et al (2013) Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 266:743–751. https://doi.org/10.1148/radiol.1212084

11. Fallonberg EM, Schmitzberger FF, Amer H et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764. https://doi.org/10.1007/s00330-016-4650-6

12. Cheung YC, Lin YC, Wan YL et al (2014) Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysis. Eur Radiol 24:2394–2403. https://doi.org/10.1007/s00330-014-3271-3

13. Sorin V, Yagil Y, Yosepovich A et al (2018) Contrast-enhanced spectral mammography in women with intermediate breast cancer risk and dense breasts. AJR Am J Roentgenol 211:W267–W274. https://doi.org/10.2214/AJR.17.19355

14. Badr S, Laurent N, Régis C et al (2014) Dual-energy contrast-enhanced digital mammography in routine clinical practice in 2013. Diagn Interv Imaging 95:245–258. https://doi.org/10.1016/j.dii.2013.10.002

15. Li L, Roth R, Germaine P et al (2017) Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): a retrospective comparison in 66 breast lesions. Diagn Interv Imaging 98:113–123. https://doi.org/10.1016/j.dii.2016.08.013

16. Perry N, Broeders M, de Wolf C et al (2006) European Commission European guidelines for quality assurance in mammography screening, 4th edn. EC, Luxembourg

17. Grin A, Horne G, Ennis M, O’Malley FP (2009) Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med 133:31–37. https://doi.org/10.1043/1543-2165-133.1.31

18. Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiasgnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447. https://doi.org/10.1056/NEJMoA1600249

19. Kim JY, Kim SH, Kim YJ et al (2015) Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging 33:72–80. https://doi.org/10.1016/j.mri.2014.08.034

20. Han M, Kim TH, Kang DK, Kim KS, Yim H (2012) Prognostic role of MRI enhancement features in patients with breast cancer: value of adjacent vessel sign and increased ipsilateral whole-breast vascularity. AJR 199:921–928. https://doi.org/10.2214/AJR.11.7895

21. Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA (2005) Gadobenate dimeglumine-enhanced MRI imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology 253:791–797. https://doi.org/10.1148/radiol.2353040733

22. Peters NH, Borel Rinkes IH, Zuithoff NP et al (2008) Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 246:116–124. https://doi.org/10.1148/radiol.2461061298

23. Huang W, Fisher PR, Dulaimy K et al (2004) Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 232:585–591. https://doi.org/10.1148/radiol.23220 30547

24. ACR Manual on Contrast Media ACR Committee on Drug and Contrast Media. (2020) Reston, VA: American College of Radiology. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf.

25. Lalji UC, Jeukens CR, Houben I et al (2015) Evaluation of low-energy contrast-enhanced spectral mammography images by comparing them to full-field digital mammography using EUREF image quality criteria. Eur Radiol 25:2813–2820. https://doi.org/10.1007/s00330-015-3695-2

26. Kuhl CK (2009) Why do purely intraductal cancers enhance on breast MR images? Radiology 253:282–283. https://doi.org/10.1148/radiol.2532091401

27. Jansen SA, Paunesku T, Fan X et al (2009) Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology 253:399–406. https://doi.org/10.1148/radiol.2533082026

28. O’Connor JP, Tofts PS, Miles KA et al (2011) Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol 84:S112–120. https://doi.org/10.1259/bjr/55166688

29. Cuened CA, Fournier L, Balvay D, Guinebretière JM (2006) Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 31:188–193. https://doi.org/10.1007/s00261-005-0386-5

30. Zurrida S, Veronesi U (2015) Milestones in breast cancer treatment. Breast J 21:3–12. https://doi.org/10.1111/tbj.12361

31. Hieken TJ, Harrison J, Herreros J, Velasco JM (2001) Correlating sonography, mammography, and pathology in the assessment of breast cancer size. Am J Surg 182:351–354. https://doi.org/10.1016/s0002-9610(01)00726-7
32. Meier-Meitinger M, Rauh C, Adamietz B et al (2012) Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. Eur J Surg Oncol 38:44–51. https://doi.org/10.1016/j.ejso.2011.10.008
33. Meier-Meitinger M, Häberle L, Fasching PA et al (2011) Assessment of breast cancer tumour size using six different methods. Eur Radiol 21:1180–1187. https://doi.org/10.1007/s00330-010-2016-z
34. Morrow M, Jagsi R, Alderman A et al (2009) Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 302:1551–1556. https://doi.org/10.1001/jama.2009.1450
35. McCaughill LE, Single RM, Aiello Bowles EJ et al (2012) Variability in reexcision following breast conservation surgery. JAMA 307:467–475. https://doi.org/10.1001/jama.2012.43
36. Schaefer FK, Eden I, Schaefer PJ et al (2007) Factors associated with one step surgery in case of non-palpable breast cancer. Eur J Radiol 64:426–431. https://doi.org/10.1016/j.ejrad.2007.02.033
37. Łuczyńska E, Niemiec J, Hendrick E et al (2016) Degree of enhancement on contrast enhanced spectral mammography (CESM) and lesion type on mammography (MG): comparison based on histological results. Med Sci Monit 22:3886–3893. https://doi.org/10.12659/msm.900371
38. Morphopoulos G, Pearson M, Ryder WD, Howell A, Harris M (1996) Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 180:44–49. https://doi.org/10.1002/(SICI)1096-9896(199609)180:1<44:AID-PATH48>3.0.CO;2-C
39. Melnikow J, Fenton JJ, Whitlock EP et al (2016) Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 164:268–278

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Anna Bozzini1 · Luca Nicosia1 · Giancarlo Pruneri2,3 · Patrick Maisonneuve4 · Lorenza Meneghetti1 · Giuseppe Renne5 · Andrea Vingiani2,3 · Enrico Cassano1 · Mauro Giuseppe MastroPasqua6,7

Anna Bozzini
anna.bozzini@ieo.it
Luca Nicosia
luca.nicosia@ieo.it
Giancarlo Pruneri
giancarlo.pruneri@istitutotumori.mi.it
Patrick Maisonneuve
patrick.maisonneuve@ieo.it
Lorenza Meneghetti
lorenza.meneghetti@ieo.it
Giuseppe Renne
giuseppe.renne@ieo.it
Andrea Vingiani
andrea.vingiani@istitutotumori.mi.it
Enrico Cassano
enrico.cassano@ieo.it

1 Division of Breast Radiology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141 Milan, Italy
2 School of Medicine, University of Milan, Milan, Italy
3 Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori Milano, Via G. Venezian, 1, 20133 Milan, Italy
4 Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141 Milan, Italy
5 Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141 Milan, Italy
6 School of Medicine, University of Bari, Bari, Italy
7 Department of Emergency and Organ Transplantations, Section of Anatomic Pathology, Piazza G. Cesare 11, 70124 Bari, Italy